RBC Capital Backs LLY with Strong Rating and 17.73% Upside Target

In late February 2026, major investment bank RBC Capital initiated coverage of pharmaceutical leader Eli Lilly, assigning the stock a bullish “Outperform” rating. The call comes with a compelling valuation thesis: analysts expect the stock to reach an average price target of $1,226.97 per share within the next year, representing nearly 18% upside from LLY’s then-recent closing price of $1,042.15.

The price target range reveals analyst confidence tempered by some caution—estimates span from a conservative $838.30 to an ambitious $1,575.00, reflecting varying views on how the company’s pipeline and commercial execution will unfold. This substantial range underscores the investment opportunity while acknowledging execution risks.

Price Forecasts and Valuation Outlook

Analysts project LLY’s annual revenue at approximately 38.6 billion, though this represents a notable 40.75% projected decline—likely reflecting market saturation expectations or competitive headwinds in key drug franchises. Meanwhile, the projected non-GAAP earnings per share lands at $19.45, painting a picture of maintaining profitability amid revenue pressures.

How Major Institutions Are Positioning LLY

Institutional investors remain heavily committed to LLY, with 5,500 funds and institutional investors holding positions in the stock. The latest quarter saw this cohort shrink by 79 holders, a modest 1.42% decline. The collective institutional portfolio weight in LLY averages 1.04%—up 9.74% from the prior quarter—suggesting renewed enthusiasm among the largest money managers.

However, total shares held by institutions actually contracted by 0.40% over the three-month period to 871.9 million shares. The put-call ratio of 1.15 suggests a bearish sentiment among options traders, contrasting with the bullish rating from RBC Capital.

Inside Moves: How Top Shareholders Are Trading

Several megafund positions reveal nuanced attitudes toward LLY. Lilly Endowment, the company’s affiliated charitable foundation, holds the largest stake at 92.2 million shares (10.30% ownership), though it trimmed its position by 3.58% from its prior 95.5 million shares.

PNC Financial Services Group maintains the second-largest institutional stake at 51.3 million shares (5.74% ownership), with a nominal 0.06% reduction. Despite cutting the absolute share count, PNC increased its portfolio weighting in LLY by 26.75%—suggesting the firm remains strategically committed even as it rebalanced overall holdings.

The Vanguard Total Stock Market Index Fund holds 27.4 million shares (3.07%), up 1.71% from prior quarter levels. Yet paradoxically, Vanguard decreased its portfolio allocation to LLY by 14.32%, likely due to index weight changes rather than conviction shifts.

Capital Research Global Investors holds 24.6 million shares (2.75% ownership), down 2.12% sequentially, but the firm bucked the broader trimming trend by increasing its portfolio weighting by 35.69%.

The Vanguard 500 Index Fund rounds out the top holders with 22.3 million shares (2.50% ownership), up 1.95% from prior quarter, though its allocation weight fell 14.48% due to index methodology adjustments.

The Takeaway on LLY

The RBC initiation signals genuine optimism about LLY’s medium-term prospects, anchored by the substantial upside target. Yet the mixed signals from the options market and the nuanced positioning by major funds suggest investors should view this as a tactical opportunity rather than an unqualified conviction call. The divergence between RBC’s bullish stance and the bearish put-call ratio highlights the debate currently playing out in markets over Eli Lilly’s near-term trajectory.